Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL2106 vs Tenuoyah in moderate-to-severe plaque psoriasis
CTR20260570Phase 3Active
- Sponsor
- Qilu Pharmaceutical
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of QL2106 in psoriasis, sponsored by Qilu Pharmaceutical. Started May 2026; status: active.
02
Drugs
QL2106
03
Conditions
psoriasis
Beyond the preview
Go deeper on CTR20260570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260570.